Core Viewpoint - Shengnuo Bio announced significant growth in revenue and net profit for the first half of 2025, indicating strong operational performance and potential for future investment opportunities [1] Financial Performance - The company achieved operating revenue of 338 million yuan, representing a year-on-year increase of 69.69% [1] - Net profit attributable to shareholders reached 88.96 million yuan, marking a substantial year-on-year growth of 308.29% [1] - The net profit after deducting non-recurring gains and losses was 89.48 million yuan, reflecting a remarkable year-on-year increase of 367.92% [1]

Group 1 - The core viewpoint of the article is that Shengnuo Bio (688117.SH) reported significant growth in its financial performance for the first half of 2025, indicating strong business momentum [1] Group 2 - The company achieved operating revenue of 338 million yuan, representing a year-on-year increase of 69.69% [1] - The net profit attributable to shareholders reached 88.96 million yuan, showing a year-on-year growth of 308.29% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 89.48 million yuan, reflecting a year-on-year increase of 367.92% [1] - The basic earnings per share were reported at 0.57 yuan [1]

天眼查商业履历信息显示，成都圣诺生物科技股份有限公司，成立于2001年，位于成都市，是一家以从 事研究和试验发展为主的企业。企业注册资本15738.5978万人民币，实缴资本5000万人民币。公司法定 代表人为文永均。 通过天眼查大数据分析，成都圣诺生物科技股份有限公司共对外投资了11家企业，参与招投标项目5 次，知识产权方面有商标信息1条，专利信息51条，此外企业还拥有行政许可31个。 来源：金融界 金融界消息 截至2025年8月13日收盘，圣诺生物（688117）报收于41.0元，上涨2.37%，换手率5.04%， 成交量7.94万手，成交金额3.22亿元。 资金流向方面，今日主力资金净流入2006.04万元，占比成交额6.23%。其中，超大单净流入1473.87万 元、占成交额4.58%，大单净流入532.17万元、占成交额1.65%，中单净流出流出1521.44万元、占成交 额4.72%，小单净流出484.60万元、占成交额1.5%。 圣诺生物最新一期业绩显示，截至2025一季报，公司营业总收入1.84亿元、同比增长77.15%，归属净利 润4711.97万元，同比增长186.06%，扣非净利润479 ...

金融界消息 截至2025年8月5日收盘，圣诺生物（688117）报收于39.75元，下跌2.14%，换手率4.62%， 成交量7.28万手，成交金额2.89亿元。 资金流向方面，今日主力资金净流出3103.31万元，占比成交额10.73%。其中，超大单净流出2940.68万 元、占成交额10.17%，大单净流出162.63万元、占成交额0.56%，中单净流出流入897.03万元、占成交 额3.1%，小单净流入2206.28万元、占成交额7.63%。 天眼查商业履历信息显示，成都圣诺生物科技股份有限公司，成立于2001年，位于成都市，是一家以从 事研究和试验发展为主的企业。企业注册资本15738.5978万人民币，实缴资本5000万人民币。公司法定 代表人为文永均。 圣诺生物最新一期业绩显示，截至2025一季报，公司营业总收入1.84亿元、同比增长77.15%，归属净利 润4711.97万元，同比增长186.06%，扣非净利润4794.31万元，同比增长213.63%，流动比率1.216、速动 比率0.712、资产负债率41.96%。 通过天眼查大数据分析，成都圣诺生物科技股份有限公司共对外投资了11家企业，参 ...

Core Viewpoint - The financing activities and stock performance of Chengdu Saintno Biological Technology Co., Ltd. indicate a mixed sentiment among investors, with significant outflows in recent days despite some net inflows [1] Financing Activities - Last week, Chengdu Saintno Biological recorded a net financing inflow of 24.62 million yuan, ranking 349th in the market [1] - The total financing amount for the week was 282 million yuan, while the repayment amount was 257 million yuan [1] Stock Performance - Over the past 5 days, the main capital outflow from Chengdu Saintno Biological was 102 million yuan, with a price drop of 5.89% [1] - In the last 10 days, the total capital outflow reached 253 million yuan, resulting in a price decline of 6.44% [1] Company Overview - Chengdu Saintno Biological Technology Co., Ltd. was established in 2001 and is located in Chengdu, focusing on research and experimental development [1] - The company has a registered capital of 1,573.85978 million yuan and a paid-in capital of 50 million yuan [1] - The legal representative of the company is Wen Yongjun [1] Investment and Intellectual Property - The company has invested in 11 enterprises and participated in 5 bidding projects [1] - In terms of intellectual property, the company holds 1 trademark and 52 patents, along with 31 administrative licenses [1]

天眼查商业履历信息显示，成都圣诺生物科技股份有限公司，成立于2001年，位于成都市，是一家以从 事研究和试验发展为主的企业。企业注册资本15738.5978万人民币，实缴资本5000万人民币。公司法定 代表人为文永均。 通过天眼查大数据分析，成都圣诺生物科技股份有限公司共对外投资了11家企业，参与招投标项目5 次，知识产权方面有商标信息1条，专利信息52条，此外企业还拥有行政许可31个。 来源：金融界 金融界消息 截至2025年7月29日收盘，圣诺生物（688117）报收于42.12元，上涨0.43%，换手率 5.22%，成交量8.21万手，成交金额3.46亿元。 资金流向方面，今日主力资金净流出1951.23万元，占比成交额5.65%。其中，超大单净流出995.44万 元、占成交额2.88%，大单净流出955.79万元、占成交额2.77%，中单净流出流入1053.51万元、占成交 额3.05%，小单净流入897.73万元、占成交额2.6%。 圣诺生物最新一期业绩显示，截至2025一季报，公司营业总收入1.84亿元、同比增长77.15%，归属净利 润4711.97万元，同比增长186.06%，扣非净利润479 ...

Group 1 - The core point of the announcement is that Chengdu Santuo Biotech Co., Ltd. has received the drug registration certificate for Ganirelix Injection from the National Medical Products Administration, which is a significant milestone for the company [1][3]. - The drug is classified as a chemical drug of category 4 and is intended for use in women undergoing controlled ovarian stimulation in assisted reproductive technology to prevent premature luteinizing hormone (LH) surges [2][3]. - The approval of Ganirelix Injection will enhance the company's product pipeline in injectable medications and improve its market competitiveness in the assisted reproduction sector, positively impacting its business development [3].

证券代码：688117 证券简称：圣诺生物 公告编号：2025-021 成都圣诺生物科技股份有限公司 关于自愿披露醋酸加尼瑞克注射液获得药品 注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都圣诺生物科技股份有限公司（以下简称"公司"）全资子公司成都圣诺 生物制药有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"） 签发的关于醋酸加尼瑞克注射液的《药品注册证书》，现将相关情况公告如下： 一、药品基本情况 受理号：CYHS2400298 药品名称：Ganirelix Injection/醋酸加尼瑞克注射液 药品注册标准编号：YBH16462025 规格：0.5ml：0.25mg（按 C₈₀H₁₁₃ClN₁₈O₁₃计） 注册分类：化学药品 4 类 申请事项：药品注册（境内生产） 上市许可持有人：成都圣诺生物制药有限公司 生产企业：成都圣诺生物制药有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及 ...

圣诺生物公告，全资子公司成都圣诺生物制药有限公司于近日收到国家药品监督管理局签发的关于醋酸 加尼瑞克注射液的《药品注册证书》。受理号：CYHS2400298；药品名称：Ganirelix Injection/醋酸加 尼瑞克注射液；药品注册标准编号：YBH16462025；规格：0.5ml：0.25mg(按C H ClN O 计)；注册分 类：化学药品4类；申请事项：药品注册(境内生产)；上市许可持有人及生产企业：成都圣诺生物制药 有限公司。该药品在辅助生殖技术中使用，用于预防过早出现促黄体激素峰。此次获得《药品注册证 书》将丰富公司注射剂产品管线，提升公司在辅助生殖领域的市场竞争力。 ...

Core Viewpoint - The Chinese innovative drug industry is experiencing significant growth in the first half of 2025, driven by policy benefits and international breakthroughs, with leading companies achieving explosive growth due to technological barriers and commercialization capabilities [1]. Company Performance Summaries - **Shuanglu Pharmaceutical**: Expected net profit for H1 2025 is between 100 million and 135 million RMB, a year-on-year increase of 237.95% to 356.24% from 29.59 million RMB in the same period last year, primarily benefiting from financial asset returns and breakthroughs in innovative drug pipelines [3][4]. - **Sino Biopharmaceutical**: Anticipated net profit ranges from 77.03 million to 94.14 million RMB, reflecting a year-on-year increase of 253.54% to 332.10%, driven by strong performance in peptide raw material exports [5][7]. - **Microchip Biotech**: Expected net profit of approximately 30.06 million RMB, representing a 173% increase, attributed to the inclusion of its core product (Sida Benamine) in medical insurance and optimized sales strategies [8][10]. - **Buchang Pharmaceutical**: Projected net profit between 488 million and 708 million RMB, a year-on-year increase of 110.88% to 205.94%, due to increased sales scale and reduced production costs [11][13]. - **Ganli Pharmaceutical**: Expected net profit of 600 million to 640 million RMB, a year-on-year increase of 100.73% to 114.12%, driven by significant revenue growth and refined expense management [15][16]. - **Shanghai Pharmaceuticals**: Anticipated net profit of 4.45 billion RMB, an increase of approximately 52% from the previous year, following the acquisition of a 10% stake in Shanghai Hengrui Medicine [17][18]. - **Liaoning Chengda**: Expected net profit between 689 million and 735 million RMB, a year-on-year increase of 50% to 60%, supported by a dual-driven strategy of healthcare and financial investment [19][21]. - **WuXi AppTec**: Projected net profit of approximately 6.3 billion RMB, a year-on-year increase of about 44.43%, driven by optimized CRDMO business models and significant non-operating gains from stock sales [23][25]. - **Notai Biopharmaceutical**: Expected net profit between 300 million and 330 million RMB, a year-on-year increase of 32.06% to 45.27%, attributed to sales growth in peptide raw materials [27][29]. - **I-Wu Biotech**: Anticipated net profit between 170 million and 180 million RMB, reflecting a year-on-year increase of 13.92% to 23.97%, focusing on allergy disease treatment products [30][31]. Industry Trends - The performance divergence in the innovative drug industry in 2025 indicates a shift from "scale competition" to "technological competition," with companies possessing genuine innovation capabilities and international layouts expected to lead, while those relying on capital operations or policy arbitrage face growth challenges [32].